4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes

ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec. 2\. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline. 3\. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline

Time frame: From baseline to up to 14 days after last dose for a total of approximately 42 days

Population: All randomized participants who received at least 1 dose of randomized study treatment.

Vital signs categorical summarization criteria: 1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); 2) supine diastolic blood pressure (DBP) \<50 mmHg; 3) supine pulse rate \<40 or \>120 beats per minute (bpm); 4) change from baseline (increase or decrease) in supine SBP greater than or equal to (\>=) 30 mmHg; 5) change from baseline (increase or decrease) in supine DBP \>= 20 mmHg.

Time frame: From baseline to up to 14 days after last dose for a total of approximately 42 days

Population: All randomized participants who received at least 1 dose of randomized study treatment.

Treatment-related adverse event (AE) was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any such events with initial onset or increasing in severity after the first dose of study treatment were counted as treatment-emergent.

Time frame: From baseline to up to 35 days after last dose for a total of approximately 63 days

Population: All randomized participants who received at least 1 dose of randomized study treatment.

Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology (hemoglobin, hematocrit, erythrocytes, reticulocytes, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils, monocytes, activated partial thromboplastin time, prothrombin time \[PT\], PT/international normalized ratio, reticulocytes); chemistry (indirect bilirubin, direct bilirubin, protein, albumin, blood urea nitrogen, creatinine, creatine kinase, urate, calcium, sodium, potassium, chloride, bicarbonate, urine urobilinogen); urinalysis (pH, urine glucose, urine ketones, urine protein, urine hemoglobin, nitrites, leukocyte esterase, urine erythrocytes, urine leukocytes, urine hyaline casts, urine bilirubin).

Time frame: From baseline to up to 14 days after last dose for a total of approximately 42 days

Population: All randomized participants who received at least 1 dose of randomized study treatment.

Percent of dose recovered in urine as unchanged drug. Ae24% = 100\* Ae24/Dose

Time frame: 0 to 24 hours post-dose on Day 28

Population: All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.

Ae was the cumulative amount of drug recovered unchanged in urine during the dosing interval, where the dosing interval was 24 hours. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Sample volume = (urine weight in gram \[g\]/1.020), where 1.020 g/mL was the approximate specific gravity of urine.

Time frame: 0 to 24 hours post-dose on Day 28

Population: All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.

Area under the concentration-time profile from time zero to time 24 hours (AUC24) was calculated as AUCtau1 +AUCtau2, where AUCtau was area under the plasma concentration-time profile from time zero to time tau (tau1 = 0 to 10 hours and tau2=10 to 24 hours). AUCtau was determined using linear/log trapezoidal method.

Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28

Population: All randomized participants who received at least 1 dose of PF-06882961 and who had at least 1 of the PK parameters of interest.

For BID dosing, parameters were calculated for both dosing intervals (0-10 hr = interval 1 and 10-24 hr = interval 2) and were displayed as Cmax1, Cmax2. Cmax1: maximum plasma concentration during the dosing interval τ1 =0 to 10 hours. Cmax2: maximum plasma concentration during the dosing interval τ2=10 to 24 hours.

Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours post dose on Day 1, 14 or 21, and 28

Population: All randomized participants treated who had at least 1 measurable concentration value.

CLr was calculated as Ae divided by AUCtau, where dosing interval is 24 hours.

Time frame: 0 to 24 hours post-dose on Day 28

Population: All randomized participants who received at least 1 dose of PF-06882961 and who have at least 1 of the PK parameters of interest.

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 28

Population: All participants randomized and treated who had at least 1 of the PK parameters of interest.

Time for Cmax, Cmax1 and Cmax2 (Tmax, Tmax1 and Tmax2) of PF-06293620 was observed directly from data as time of first occurrence.

Time frame: 0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hrs post dose on Day 1, 14 or 21, and 28

Population: All participants randomized and treated who had at least 1 of the PK parameters of interest.